Bone Marrow

Hypoxic pre-conditioning increases the infiltration of endothelial cells into scaffolds for dermal regeneration pre-seeded with mesenchymal stem cells

Fernando A. Fierro, Adam J. O’Neal , Julie R. Beegle, Myra N. Chávez, Thomas R. Peavy, Roslyn R. Isseroff , and José T. Egaña

Front Cell Dev Biol. 2015; 3: 68. Published online 2015 Oct 30

Here we describe human bone marrow-derived MSC seeded in Integra matrices, a common type of scaffold for dermal regeneration (SDR). We show and measured the distribution of MSC within the SDR, where cells clearly establish physical interactions with the scaffold, exhibiting constant metabolic activity for at least 15 days.

Bone regeneration in calvarial defects in a rat model by implantation of human bone marrow-derived mesenchymal stromal cell spheroids

Hideyuki Suenaga, Katsuko S. Furukawa, Yukako Suzuki, Tsuyoshi Takato, Takashi Ushida

Journal of Materials Science: Materials in Medicine November 2015

Mesenchymal stem cell (MSC) condensation contributes to membrane ossification by enhancing their osteodifferentiation. We investigated bone regeneration in rats using the human bone marrow-derived MSC-spheroids prepared by rotation culture, without synthetic or exogenous biomaterials.

Suppression of cancer relapse and metastasis by inhibiting cancer stemness

Youzhi Li, Harry A. Rogoff, Sarah Keates, Yuan Gao, Sylaja Murikipudi, Keith Mikule, David Leggett, Wei Li, Arthur B. Pardee, and Chiang J. Li

PNAS | February 10, 2015 | vol. 112 | no. 6 | 1839–1844

Here we show that BBI608, a small molecule identified by its ability to inhibit gene transcription driven by Stat3 and cancer stemness properties, can inhibit stemness gene expression and block spherogenesis of or kill stemness-high cancer cells isolated from a variety of cancer types. Moreover, cancer relapse and metastasis were effectively blocked by BBI608 in mice.

Human Mesenchymal Stromal/Stem Cell-Mediated Bone Marrow Organization

Yasuo Miura , Tatsuo Ichinohe, Taira Maekawa

Japanese Journal of Transfusion and Cell Therapy Vol. 61 (2015) No. 5 p. 489-490

Mesenchymal stromalstem cells (MSCs) in bone marrow differentiate into cellular components of the hematopoietic cell niche, including osteogenic cells. A human MSC transplantation into mice (xenotransplantation model) is one of the best available in vivo models to recapitulate MSC-mediated bone and bone marrow organization.

A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies

SY Kim , J-W Theunissen , J Balibalos , S Liao-Chan , MC Babcock , T Wong , B Cairns , D Gonzalez , EH van der Horst , M Perez , Z Levashova , L Chinn , JA D‘Alessio , M Flory , A Bermudez , DY Jackson , E Ha , J Monteon , MF Bruhns , G Chen, and T-S Migone

Citation: Blood Cancer Journal (2015) 5, e316; doi:10.1038/bcj.2015.39 Published online 29 May 2015

Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin’s lymphoma.